Drug intelligence / Profile preview

lidocaine + ketamine

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Intravenous, Transdermal, Topical
01

Overview

Lidocaine + ketamine is a combination of two pharmaceutical agents commonly used in pain management and anesthesia. Lidocaine is an amide local anesthetic that works primarily by blocking sodium channels, thereby inhibiting nerve signal transmission and providing analgesia. Ketamine is a dissociative anesthetic that acts as an antagonist at the N-methyl-D-aspartate receptor (NMDA receptor), reducing central sensitization and modulating pain perception. Ketamine also interacts with opioid receptors, sodium channels, potassium channels, and may affect neurotransmitter release such as glutamate. The combination leverages both peripheral (lidocaine) and central (ketamine) mechanisms to provide multimodal analgesia for acute or chronic pain conditions—including neuropathic pain—and can be administered intravenously or transdermally[1][2][4][6]. This combination has been studied for use in perioperative anesthesia, pediatric sedation, chronic low back pain, neuropathic pain syndromes, and other neurologic or chronic pain disorders[1][2][4][6].

Other names
local anesthetic + ketamine
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)KCNK2 (Potassium channel subfamily K member 2)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on lidocaine + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + ketamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call